Organon & Co. OGN R3KPHARMA
Company Overview
Organon & Co. develops and delivers women health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, China, Latin America, the Middle East, Russia, Africa, and internationally. The company's women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, Marvelon, and Mercilon to prevent pregnancy; Follistim AQ, which is used to promote development of ovarian follicles; Elonva, a follicle stimulant; Ganirelix acetate injection, an injectable antagonist; Jada for abnormal postpartum uterine bleeding and hemorrhage; and Xaciato for bacterial vaginosis. Its biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; oncology products, including Ontruzant and Aybintio; Bildyos and Bilprevda, a recombinant anti-RANKL human monoclonal antibodies; and Poherdy, a neu receptor antagonist. The company also offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Atozet, Rosuzet, and Zocor brands; Cozaar and Hyzaar for hypertension; respiratory products to control and prevent asthma symptoms under the Singulair, Dulera, Zenhale, and Asmanex brands, as well as seasonal allergic rhinitis under the Nasonex, Clarinex, and Aerius brands. In addition, it provides dermatology products under the Vtama, Diprosone, and Elocon brand; bone health products under the Fosamax brand; and non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brands, as well as Proscar for symptomatic benign prostatic hyperplasia; and Propecia for male pattern hair loss. The company serves drug wholesalers and retailers, hospitals, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions. Organon & Co. was founded in 1923 and is headquartered in Jersey City, New Jersey.
Why Investors Should Care
Generates a return on equity of 24.0%, reflecting efficient use of shareholder capital.
Trades at a P/E of 17.6, below the sector median of 24.8.
Operating margin of 20.7% supports profitability.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $6.22B (-2.9% YoY); net profit $187.00M.
- Trailing 12 Months Year-on-year growth — revenue -2.3%, earnings -28.3%.
- 5-Year Trend Long-term compounding — revenue CAGR -4.4%, profit CAGR -43.4%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | -4.38% |
| 1 Year: | -2.30% |
Compounded Profit Growth
| 5 Years: | -43.40% |
| 1 Year: | -28.30% |
Stock Price Performance
| 1 Year: | +48.20% |
| 6 Months: | +111.19% |
| 3 Months: | +2.84% |
| 1 Month: | +1.25% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)65.71 · Neutral
P/E of 17.63 is below the sector median of 24.83 — relatively cheaper than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Strong return on equity of 24.0%.
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Revenue declined at -4.4% CAGR over 5 years.
- Earnings shrank at -43.4% CAGR over 5 years.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | OGN Organon & Co. R3KPHARMA | 13.75 | 17.63 | $3.61B | 0.58% | 11.70% | 24.04% | -4.38% | -43.40% |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.78B | 1.53B | 1.61B | 1.51B | 1.59B | 1.60B | 1.57B | 1.58B | 1.54B | 1.54B | 1.61B | 1.52B | 1.62B | 1.61B | 1.58B | - | - | 1.59B | 1.60B | 1.51B | 1.46B | 1.56B |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 720.00M | 745.00M | 766.00M | 677.00M | 711.00M |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | 968.00M | 907.00M | 957.00M | 939.00M | 923.00M | - | - | 874.00M | 857.00M | 741.00M | 783.00M | 847.00M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 548.00M | 499.00M | 524.00M | 517.00M | 524.00M |
| Operating Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 326.00M | 358.00M | 217.00M | 266.00M | 323.00M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 449.00M | 463.00M | 69.00M | 410.00M | 371.00M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 131.00M | 128.00M | 121.00M | 111.00M | 108.00M |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 229.00M | 243.00M | -148.00M | 213.00M | 183.00M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 84.00M | 83.00M | 57.00M | 67.00M | 75.00M |
| Net Income | 703.00M | 542.00M | 547.00M | 399.00M | 427.00M | 323.00M | 348.00M | 234.00M | 227.00M | 177.00M | 242.00M | 58.00M | 201.00M | 195.00M | 359.00M | - | - | 145.00M | 160.00M | -205.00M | 146.00M | 108.00M |
| Diluted EPS | 2.78 | 2.14 | 2.16 | 1.58 | 1.68 | 1.27 | 1.36 | 0.92 | 0.89 | 0.69 | 0.95 | 0.23 | 0.78 | 0.75 | 1.38 | - | - | 0.56 | 0.61 | -0.79 | 0.55 | 0.40 |
| R&D Expense | 45.00M | 51.00M | 54.00M | 67.00M | 76.00M | 111.00M | 96.00M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | 7.78B | 6.53B | - | 6.17B | 6.26B | 6.40B | 6.22B |
| Cost of Revenue | - | - | - | 2.29B | 2.52B | 2.69B | 2.90B |
| Gross Profit | - | - | - | 3.88B | 3.75B | 3.71B | 3.31B |
| Operating Expenses | - | - | - | 2.17B | 2.42B | 2.23B | 2.09B |
| Operating Income | - | - | - | 1.71B | 1.33B | 1.49B | 1.23B |
| EBITDA | - | - | - | 1.76B | 1.44B | 1.60B | 1.29B |
| Interest Expense | - | - | - | 422.00M | 527.00M | 520.00M | 504.00M |
| Pretax Income | - | - | - | 1.12B | 673.00M | 807.00M | 425.00M |
| Tax Provision | - | - | - | 205.00M | -350.00M | -57.00M | 238.00M |
| Net Income | 3.22B | 2.16B | - | 917.00M | 1.02B | 864.00M | 187.00M |
| Diluted EPS | 12.69 | 8.52 | - | 3.59 | 3.99 | 3.33 | 0.72 |
| R&D Expense | 220.00M | 210.00M | 443.00M | - | - | - | - |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 10.11B | - | 10.96B | 12.06B | 13.10B | 12.87B |
| Current Assets | - | - | - | - | 3.93B | 4.51B | 4.35B | 4.35B |
| Cash & Equivalents | - | - | 12.00M | - | 706.00M | 693.00M | 675.00M | 574.00M |
| Inventory | - | - | - | - | 1.00B | 1.31B | 1.32B | 1.41B |
| Receivables | - | - | - | - | 1.48B | 1.74B | 1.36B | 1.33B |
| Total Liabilities | - | - | - | - | 11.85B | 12.13B | 12.63B | 12.12B |
| Current Liabilities | - | - | 2.67B | - | 2.51B | 2.92B | 2.72B | 2.39B |
| Long Term Debt | - | - | 0 | - | 8.90B | 8.75B | 8.86B | 8.63B |
| Total Debt | - | - | - | - | 8.91B | 8.76B | 8.88B | 8.64B |
| Total Equity | 6.35B | 7.04B | 5.49B | - | -892.00M | -70.00M | 472.00M | 752.00M |
| Shares Outstanding | - | - | - | - | 254.37M | 255.63M | 257.80M | 260.32M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | 858.00M | 799.00M | 939.00M | 700.00M |
| Investing Cash Flow | - | - | - | -420.00M | -260.00M | -513.00M | -390.00M |
| Financing Cash Flow | - | - | - | -433.00M | -569.00M | -368.00M | -561.00M |
| Capital Expenditure | -92.00M | -255.00M | - | -427.00M | -261.00M | -351.00M | -316.00M |
| Free Cash Flow | - | - | - | 431.00M | 538.00M | 588.00M | 384.00M |
| Net Change in Cash | - | - | - | 5.00M | -30.00M | 58.00M | -251.00M |
| Dividends Paid | 0 | 0 | 145.00M | 290.00M | 294.00M | 297.00M | 88.00M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | 62.8% | 59.8% | 58.0% | 53.3% |
| Operating Margin % | - | - | - | 27.6% | 21.2% | 23.2% | 19.7% |
| Net Margin % | 41.4% | 33.1% | - | 14.9% | 16.3% | 13.5% | 3.0% |
| ROE % | 45.7% | 39.4% | - | -102.8% | -1,461.4% | 183.1% | 24.9% |
| ROCE % | - | - | - | 20.2% | 14.5% | 14.3% | 11.7% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 12.21% | 32.06M | $438.54M |
| 2 | Pentwater Capital Management Lp | 6.89% | 18.10M | $247.61M |
| 3 | Vanguard Portfolio Management LLC | 5.76% | 15.13M | $207.01M |
| 4 | Vanguard Capital Management LLC | 4.54% | 11.91M | $162.93M |
| 5 | State Street Corporation | 3.68% | 9.66M | $132.14M |
| 6 | Goldman Sachs Group Inc | 1.98% | 5.20M | $71.12M |
| 7 | UBS Group AG | 1.85% | 4.86M | $66.44M |
| 8 | Geode Capital Management, LLC | 1.83% | 4.82M | $65.88M |
| 9 | Alliancebernstein L.P. | 1.81% | 4.75M | $65.04M |
| 10 | Man Group PLC | 1.59% | 4.18M | $57.19M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for OGN
Organon & Co. (OGN) is Attracting Investor Attention: Here is What You Should Know - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMioAFBVV95cUxONURCVlZKdXlzUHpYSlJZWkEyTU9CTmkyN00xUmRnbzJYTWdxMXNQRFJlclJrU1hFSDJkZ2VHTzZRcm04a0ZwMmlUVkFhU1REZzJjOWVOMXdXWWVBWGtVOE81RDVjVmlVWTlkejRiZXkzM2cwQUswSUdxYU1HTUo1R0NjQjJERVp5NkF1VG…
OGN - Organon & Co Stock Price and Quote - Finviz
<a href="https://news.google.com/rss/articles/CBMiREFVX3lxTE9TYUg0MFMwWVk4eFJVMEt4dkVKWTRqYW9NdlVVdFBYcUxqcS1FOXRsZHZLU2FyVDM1dXRHMndhQ2h0VWdl?oc=5" target="_blank">OGN - Organon & Co Stock Price and Quote</a> <font color="#6f6f6…
Organon (OGN) Stock Sinks As Market Gains: Here's Why - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMimwFBVV95cUxPSDVoQVVrMG9Gek1NSHdaZC1fRC1xRlhGWlJTNU9ZeWJzckV1Yi1OQmlBb081c0ZHM1RZVWE0ZEVMNmgwZmo0RHlFSGhINmVHeFpkVUo2ZTRxNDNYaEF5LUVoeTZkVFVPcXprNGl4bzdpZ1hYNDJMdnZmX2dmU3VhZnpzNGdMSjJQVkZMTW…
Investors Heavily Search Organon & Co. (OGN): Here is What You Need to Know - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMiogFBVV95cUxObU83X2NoT0RfaVhBTEt4Q2Y1UHZwajBjdDdBMEdiZG1wMW5BRUpaMV9BNGM2bE9uanpZSVc3U1E4eE1NVUpsa2tPekJ4Y29aVGxkdkVsd2g1dllDbVBMQUt3RF9QbHd4S2JzRUlidEJZX1VMbXRSUElOMGpuTDZaY1RhNXRfVzhxRHF4b3…
Organon (OGN) Stock Drops Despite Market Gains: Important Facts to Note - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMinAFBVV95cUxPVzY0N0I5WFFIQUN4R25idTAzV3N0ZUVfZjFWeUw0Z3NfSmt4dEo2aFozZkZTS3M0X2VkcjZmNzh1YXQtZzIyVFN2WnJtblJmUERoZTUtVkN5VlQ0RVl1NExOcTJPY0NQd0FtNWVoT2Z2VWh1WVp3NEVXbzZCa0tCTXNwazFGMG5JM1BGYk…
3 Reasons to Avoid OGN and 1 Stock to Buy Instead - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMijwFBVV95cUxQZ2d6TEZpeVp6OGMwSzlLT0phdWxMWnU3Y3ZiVDJLYXd4bGltNTJlNnVxbkRqbzNhLWkwTEdxd2dnckFIVXNsMTVXVHNBcHJtS2NuOEY2WlAzd0pRMExETVlPR0xwdWxrVFpmNzRzbVJUV2ZqcTNFVW5fWjYxUHFoVk41U3lRZ05MQnBBNz…
OGN — Frequently Asked Questions
What is the current share price of Organon & Co. (OGN)?
As of 2026-09-19 21:16 PDT, Organon & Co. (OGN) trades at $13.75 on NYSE. Its 52-week range is $5.68 to $13.78.
What is the market capitalisation of OGN?
Organon & Co. (OGN) has a market capitalisation of $3.61B on NYSE.
What is the P/E ratio of OGN?
OGN trades at a trailing price-to-earnings (P/E) ratio of 17.63. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 3.57.
Does OGN pay a dividend?
Organon & Co. (OGN) currently offers a dividend yield of 0.58%.
What is the return on equity (ROE) of OGN?
OGN has a return on equity (ROE) of 24.04%. Its return on capital employed (ROCE) is 11.70%.
Is OGN a good stock to buy?
This page provides a data-driven analysis of Organon & Co. (OGN), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.